
    
      The drug will be administered intravenously on days 1, 8, and 15 of each 28-day cycle.
      Patients who do not meet the definition of treatment failure after the first cycle may
      receive up to five additional cycles of therapy. .

      After completion of study treatment, patients are followed for 1 year.
    
  